These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610 [TBL] [Abstract][Full Text] [Related]
29. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169 [TBL] [Abstract][Full Text] [Related]
30. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Xaubet A; Serrano-Mollar A; Ancochea J Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635 [TBL] [Abstract][Full Text] [Related]
31. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Kreuter M; Wälscher J; Behr J Curr Opin Pulm Med; 2017 Sep; 23(5):418-425. PubMed ID: 28622199 [TBL] [Abstract][Full Text] [Related]
32. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523 [TBL] [Abstract][Full Text] [Related]
33. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis. Covvey JR; Mancl EE Ann Pharmacother; 2014 Dec; 48(12):1611-9. PubMed ID: 25202034 [TBL] [Abstract][Full Text] [Related]
34. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. King CS; Nathan SD Curr Opin Pulm Med; 2015 Sep; 21(5):479-89. PubMed ID: 26164298 [TBL] [Abstract][Full Text] [Related]
35. Current and Future Idiopathic Pulmonary Fibrosis Therapy. Richeldi L; Baldi F; Pasciuto G; Macagno F; Panico L Am J Med Sci; 2019 May; 357(5):370-373. PubMed ID: 31010462 [TBL] [Abstract][Full Text] [Related]
36. Antibody-based therapies for idiopathic pulmonary fibrosis. Sgalla G; Flore M; Siciliano M; Richeldi L Expert Opin Biol Ther; 2020 Jul; 20(7):779-786. PubMed ID: 32098521 [TBL] [Abstract][Full Text] [Related]
37. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. Ren H; Wang K; Yang H; Gao L Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145 [TBL] [Abstract][Full Text] [Related]
40. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]